Update chronische Nierenerkrankung

Folgt man den aktuellen KDIGO-Empfehlungen zur Definition der chronischen Nierenerkrankung, so ist in Deutschland jeder siebte Erwachsene chronisch nierenkrank. Aus geschätzter glomerulärer Filtrationsrate und Albuminurie lässt sich das individuelle Risiko der CKD-Progression (CKD = chronic kidney disease) abschätzten. Interventionsziele sind eine Progressionshemmung der chronischen Nierenerkrankung, eine Primär- oder Sekundärprävention kardiovaskulärer Ereignisse, die Behandlung exokriner und endokriner Funktionsstörungen und die rechtzeitige Vorbereitung einer Nierenersatztherapie.

When applying the current KDIGO recommendations on the definition of chronic kidney disease (CKD) every seventh adults in Germany suffers from chronic kidney disease. The individual risk for CKD progression can be estimated from the glomerular filtration rate and albuminuria. The objectives of medical interventions are prevention of CKD progression, primary or secondary prevention of cardiovascular events, treatment of exocrine and endocrine dysfunctions and the timely preparation for kidney replacement therapy.

Key words

Chronic kidney disease - glomerular filtration rate - albuminuria - CKD progression - plasma cystatin C - Cockcroft-Gault equation - proteinuria

• Literatur

• 1 Kidney International Supplements. 2013; 3: 19-62
• 2 Girndt M, Trocchi P, Scheidt-Nave C et al. The Prevalence of Renal Failure. Dtsch Arztebl Int 2016; 113: 85-91
• 3 Fotheringham J, Campbell MJ, Fogarty DG et al. Estimated albumin excretion rate versus urine albumin-creatinine ratio for the estimation of measured albumin excretion rate: derivation and validation of an estimated albumin excretion rate equation. Am J Kidney Dis 2014; 63: 405-414
• 4 Tangri N, Stevens LA, Griffith J et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305: 1553-1559
• 5 Tangri N, Grams ME, Levey AS et al. KD Prognosis Consortium. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA 2016; 315: 164-174
• 6 Fried LF, Emanuele N, Zhang JH et al. VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903
• 7 Appel LJ, Wright Jr JT, Greene T et al. AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929
• 8 Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762
• 9 Wanner C, Inzucchi SE, Lachin JM et al. EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
• 10 Baigent C, Landray MJ, Reith C et al. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
• 11 Wanner C, Krane V, März W et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
• 12 Fellström BC, Jardine AG, Schmieder RE et al. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
• 13 Rogacev KS, Pinsdorf T, Weingärtner O et al. Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients. Clin J Am Soc Nephrol 2012; 7: 943-948
• 14 Singh AK, Szczech L, Tang KL et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
• 15 Drüeke TB, Locatelli F, Clyne N et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
• 16 Pfeffer MA, Burdmann EA, Chen CY et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032